- Home
- EU vs EYPT Comparison
EU vs EYPT Comparison
Compare EU & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EU | EYPT |
|---|---|---|
| Founded | 2009 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.7M | 1.3B |
| IPO Year | 2011 | 2005 |
Fundamental Metrics
Financial Performance| Metric | EU | EYPT |
|---|---|---|
| Price | $1.94 | $13.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 2.2M | 852.2K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,155,000.00 | $7,539,000.00 |
| Revenue This Year | $212.11 | N/A |
| Revenue Next Year | $29.88 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $5.46 |
| 52 Week High | $4.19 | $19.11 |
Technical Indicators
Market Signals| Indicator | EU | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 46.88 |
| Support Level | $1.71 | $13.61 |
| Resistance Level | $2.17 | $14.54 |
| Average True Range (ATR) | 0.14 | 0.62 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 47.87 | 47.10 |
Price Performance
Historical ComparisonAbout EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.